Answers are grounded in this paper and cite their sources.
Endometrial neuroendocrine carcinoma (NEC) is a rare non-endometrioid subtype of endometrial carcinoma characterized by aggressive behavior and poor prognosis. For endometrial large cell neuroendocrine carcinoma (LCNEC), the reported median overall survival (OS) is approximately 11 months, and the 5-year OS rate is approximately 23%; most patients are diagnosed at advanced stages (FIGO stage III/IV). Molecular studies of endometrial NEC remain limited, although alterations involving PTEN and PIK3CA and mismatch repair deficiency (dMMR) have been reported. Herein, we report endometrial LCNEC in a 52-year-old patient harboring the pathogenic POLE exonuclease-domain variant p.V411L, a rarely reported molecular finding in this histological subtype. The patient underwent surgery followed by two cycles of nab-paclitaxel plus carboplatin, external-beam radiotherapy and brachytherapy, and two additional chemotherapy cycles. At the last follow-up on September 9, 2026, no local recurrence or distant metastasis was identified. Molecular testing supported classification as POLE -mutated endometrial carcinoma. This report describes the clinicopathological and molecular characteristics, treatment, and short-term outcome of this rare case.
No takes yet. Share an insight, caveat, or question.
Pu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: